- Trial phase
- Approved (FDA)
- Time to market
- Already on the market. FDA-approved August 2023, currently generating commercial revenue.
- Why 4/10
- HEPZATO KIT is already FDA-approved and commercially launched with no pending regulatory decision (PDUFA). The next hard, dated catalysts are quarterly earnings reports, which are not binary events. The Phase 2 breast cancer trial is too early (first patient dosed July 2026) for a pivotal readout within 12 months. As an approved, revenue-generating product at a company with a market cap that reflects its commercial trajectory, the impact score is 4.
With no binary FDA catalyst ahead, the stock's near-term direction hinges on commercial execution: watch Q4 2026 earnings (expected early 2027) for continued HEPZATO KIT revenue growth and treatment center expansion. The Phase 2 breast cancer trial is an important long-term value driver but is unlikely to produce pivotal data within 12 months. The stock's 52-week high near $22.32 and strong institutional accumulation suggest the market is already pricing in the current growth trajectory.
Price Chart
Executive Summary
HEPZATO KIT is Delcath Systems' FDA-approved liver-directed therapy for metastatic uveal melanoma, delivering high-dose melphalan chemotherapy directly to the liver via a proprietary perfusion system. Approved in August 2023, it is the first and only FDA-approved liver-directed treatment for its indication and is generating rapidly growing commercial revenue ($32.7M in Q3 2026, up 70% YoY). The company raised full-year 2026 guidance to $115M-$117M, has strong institutional backing (BlackRock, Vanguard), and a bullish analyst consensus (11 buy/strong buy vs 1 hold, mean price target $28.60). A Phase 2 trial in liver-dominant metastatic breast cancer is underway but early-stage. The stock trades near its 52-week high of $22.32.
How It Works
HEPZATO KIT delivers the chemotherapy drug melphalan directly to the liver through a catheter, while a filtration system isolates the liver's blood supply to prevent the drug from circulating throughout the body. This approach (called percutaneous hepatic perfusion, or PHP) allows a much higher dose of chemotherapy to reach liver tumors than would be possible with standard intravenous delivery, while reducing side effects elsewhere in the body.
Trial Status
HEPZATO KIT was FDA-approved on August 14, 2023 as the first liver-directed therapy for unresectable hepatic-dominant metastatic uveal melanoma. It is commercially available in the U.S. through a network of over 31 active treatment centers. A Phase 2 clinical trial for liver-dominant metastatic breast cancer began dosing patients in July 2026. The European version (CHEMOSAT) was included in ESMO-EURACAN clinical practice guidelines for uveal melanoma in April 2026.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 earnings report (early 2027) - commercial revenue growth trajectory
- Phase 2 breast cancer trial interim data readout (timing uncertain, likely 2027+)
- Expansion of active treatment centers (targeting 36+ by end of 2026)
- Potential label expansion into additional liver-dominant cancer indications
Source Filing
The SecBot filing or press-release report that triggered this drug report:
DELCATH SYSTEMS, INC. 8-K DCTH ·Originating report